Goldman Sachs Group Inc. Has $207.15 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Goldman Sachs Group Inc. lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating) by 7.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 314,591 shares of the company’s stock after selling 26,020 shares during the quarter. Goldman Sachs Group Inc. owned 0.37% of IDEXX Laboratories worth $207,146,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. EverSource Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $28,000. Bell Investment Advisors Inc acquired a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at $34,000. Institutional & Family Asset Management LLC boosted its holdings in shares of IDEXX Laboratories by 216.7% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 57 shares of the company’s stock valued at $35,000 after purchasing an additional 39 shares in the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $39,000. Finally, Exane Derivatives bought a new position in shares of IDEXX Laboratories in the 4th quarter valued at $40,000. 84.92% of the stock is currently owned by hedge funds and other institutional investors.

IDXX has been the subject of several analyst reports. Atlantic Securities initiated coverage on IDEXX Laboratories in a research report on Tuesday, February 8th. They set an “overweight” rating and a $650.00 target price for the company. Bank of America lowered IDEXX Laboratories from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $550.00 to $470.00 in a research report on Thursday, May 5th. lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, May 6th. Finally, William Blair reiterated an “outperform” rating on shares of IDEXX Laboratories in a report on Wednesday, February 2nd. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to, the company currently has a consensus rating of “Buy” and an average target price of $663.67.

Shares of NASDAQ:IDXX traded up $14.23 during mid-day trading on Friday, reaching $362.18. The company had a trading volume of 833,844 shares, compared to its average volume of 824,767. The company has a current ratio of 1.12, a quick ratio of 0.81 and a debt-to-equity ratio of 1.21. The firm has a market cap of $30.43 billion, a price-to-earnings ratio of 42.46, a PEG ratio of 2.13 and a beta of 1.10. The company’s 50-day moving average price is $487.03 and its 200-day moving average price is $545.45. IDEXX Laboratories, Inc. has a one year low of $330.66 and a one year high of $706.95.

IDEXX Laboratories (NASDAQ:IDXXGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported $2.27 EPS for the quarter, topping analysts’ consensus estimates of $2.25 by $0.02. The company had revenue of $836.55 million for the quarter, compared to analysts’ expectations of $836.47 million. IDEXX Laboratories had a net margin of 22.43% and a return on equity of 103.70%. IDEXX Laboratories’s revenue was up 7.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.35 EPS. On average, research analysts anticipate that IDEXX Laboratories, Inc. will post 8.24 EPS for the current fiscal year.

In other news, Director Jonathan W. Ayers sold 250 shares of the business’s stock in a transaction on Tuesday, February 15th. The shares were sold at an average price of $509.70, for a total transaction of $127,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.06% of the company’s stock.

IDEXX Laboratories Profile (Get Rating)

IDEXX Laboratories, Inc develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.

See Also

Want to see what other hedge funds are holding IDXX? Visit to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXGet Rating).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with's FREE daily email newsletter.